Chronic obstructive pulmonary disease

4 clinical trials have treated >120 patients suffering from COPD without
reporting any adverse event while also indicating a significant treatment effect

Key Insights

Less Hospital Admissions: In one of the studies, there was a significant decrease in the number of hospital admissions in the treatment group compared to the control group.

Improved Breathing Capacity: Each of the four trials was able to show efficacy. For instance, expiratory volume (FEV1) & diffusing capacity for carbon monoxide improved. Results on the 6-minute walk test has also been shown to improve after MSC administration.

Excellent Safety Profile: Of 120 patients treated no treatment associated adverse event is reported.

Clinical trials

Squassoni, S.D. et al. (2021) ‘Autologous infusion of bone marrow and mesenchymal stromal cells in patients with chronic obstructive pulmonary disease: Phase I randomized clinical trial’, International Journal of Chronic Obstructive Pulmonary Disease, Volume 16, pp. 3561–3574. doi:10.2147/copd.s332613.

Armitage, J. et al. (2018) ‘Mesenchymal stromal cell infusion modulates systemic immunological responses in stable COPD patients: A phase I pilot study’, European Respiratory Journal, 51(3), p. 1702369. doi:10.1183/13993003.02369-2017.

Weiss, D.J. et al. (2021) ‘Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP Levels’, Respiratory Research, 22(1). doi:10.1186/s12931-021-01734-8.

Weiss, D.J. et al. (2013) ‘A placebo-controlled, randomized trial of mesenchymal stem cells in COPD’, Chest, 143(6), pp. 1590–1598. doi:10.1378/chest.12-2094.